4-溴-N,2-二乙基苯胺 | 81090-37-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-溴-N,2-二乙基苯胺
• 英文名称: 4-bromo-N,2-diethylaniline
• 英文别名: 2,N-diethyl-4-bromo-aniline；2,N-Diaethyl-4-brom-anilin；N-ethyl-4-bromo-2-ethylaniline
• CAS: 81090-37-1
• 化学式: C₁₀H₁₄BrN
• 分子量: 228.132
• InChiKey: BDJLKPUFQWYGBC-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：
  按规定使用和贮存的物质不会分解，并应避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921420090
• 储存条件：
  请将药品存放在密闭、阴凉、干燥的地方。

反应信息

• 作为反应物：
  描述：

  4-溴-N,2-二乙基苯胺 在 potassium carbonate 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 52.67h， 生成 4-(diethylamino)-3-ethylbenzaldehyde
  参考文献：
  名称：

  供体取代的二苯乙烯基吡嗪类化合物：空间拥挤对UV-Vis吸收和荧光的影响

  摘要：

  通过两次醇醛缩合制备在氮上和相邻位置具有大量取代基的二（对氨基苯乙烯基）吡嗪。吸收和发射光谱受空间位阻增加的影响，因为氮和π系统之间的轨道交叠受到大量基团的调节。强烈的溶剂化变色现象和巨大的斯托克斯频移是由于激发态下供体-受体相互作用的放大所致。质子化首先发生在末端氨基，然后是中央吡嗪的质子化。随着酸强度的增加，吸收光谱和发射光谱首先会变为蓝色，然后再发生红移。版权所有©2012 John Wiley＆Sons，Ltd.

  DOI：

  10.1002/poc.2978
• 作为产物：
  描述：

  4-溴-2-乙基乙酰苯胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以50%的产率得到4-溴-N,2-二乙基苯胺
  参考文献：
  名称：

  供体取代的二苯乙烯基吡嗪类化合物：空间拥挤对UV-Vis吸收和荧光的影响

  摘要：

  通过两次醇醛缩合制备在氮上和相邻位置具有大量取代基的二（对氨基苯乙烯基）吡嗪。吸收和发射光谱受空间位阻增加的影响，因为氮和π系统之间的轨道交叠受到大量基团的调节。强烈的溶剂化变色现象和巨大的斯托克斯频移是由于激发态下供体-受体相互作用的放大所致。质子化首先发生在末端氨基，然后是中央吡嗪的质子化。随着酸强度的增加，吸收光谱和发射光谱首先会变为蓝色，然后再发生红移。版权所有©2012 John Wiley＆Sons，Ltd.

  DOI：

  10.1002/poc.2978

文献信息

• [EN] 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION<br/>[FR] DERIVES DE BENZIMIDAZOLE SUBSTITUES EN 5- OU 6- UTILISES EN TANT QU'INHIBITEURS DE LA REPLICATION DU VIRUS RESPIRATOIRE SYNCITIAL
  申请人：TIBOTEC PHARM LTD

  公开号：WO2005058874A1

  公开（公告）日：2005-06-30

  The present invention concerns 5- or 6-substituted-benzimidazole derivatives having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I) a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein Q is Ar2, R6, pyrrolidinyl substituted with R6, piperidinyl substituted with R6 or homopiperidinyl substituted with R6, G is a direct bond or optionally substituted C1-10alkanediyl; R1 is Arl or a monocyclic or bicyclic heterocycle; one of R 2a and R2b is cyanoCl-6alkyl, cyanoC2-6alkenyl, Ar3Cl-6alkyl, Het­-C1-6alky1, N(R8aR8b)Cl-6alkyl, Ar3C2-6alkenyl, Het-C2-6alkenyl, Ar3 aminoCl-6alkyl, Het­aminoCl-6alkyl, Ar3thioC1-6 alkyl, Het-thioC1-6alkyl, Ar3sulfonylC1-6 alkyl, Het­sulfonylC1-6alkyl, Ar3aminocarbonyl, Het-aminocarbonyl, Ar3(CH2)naminocarbonyl, Het-(CH2)naminocarbonyl, Ar3carbonylamino, Het-carbonylamino, Ar3(CH2)ncarbonylamino, Het-(CH2)ncarbonylamino, and the other one of R2a and R2b is hydrogen; in case R2a is hydrogen, then R3 is hydrogen; in case R2b is hydrogen, the R3 is hydrogen or C1-6alkyl. It further concerns their preparation and compositions comprising them, as well as their use as a medicine.

  本发明涉及对呼吸道合胞病毒复制具有抑制活性的5-或6-取代苯并咪唑衍生物，其具有���下式(I)的结构：一种前药、N-氧化物、加成盐、季铵盐、金属配合物或其立体化异构体，其中Q为Ar2、R6、用R6取代的吡咯烷基、用R6取代的哌啶基或用R6取代的环己胺基，G为直链键或可选择取代的C1-10烷二基；R1为Arl或单环或双环杂环；R2a和R2b中的一个为氰基C1-6烷基、氰基C2-6烯基、Ar3C1-6烷基、Het-C1-6烷基、N(R8aR8b)C1-6烷基、Ar3C2-6烯基、Het-C2-6烯基、Ar3氨基C1-6烷基、Het氨基C1-6烷基、Ar3硫基C1-6烷基、Het-硫基C1-6烷基、Ar3磺酰基C1-6烷基、Het-磺酰基C1-6烷基、Ar3氨基羰基、Het-氨基羰基、Ar3(CH2)n氨基羰基、Het-(CH2)n氨基羰基、Ar3羰基氨基、Het-羰基氨基、Ar3(CH2)n羰基氨基、Het-(CH2)n羰基氨基，R2a和R2b中的另一个为氢；如果R2a为氢，则R3为氢；如果R2b为氢，则R3为氢或C1-6烷基。本发明还涉及它们的制备和包含它们的组合物，以及它们作为药物的用途。
• New Compounds. Some Aryl and Aralkyl Ureas
  作者：Johannes Buck、Richard Baltzly、Alan Ardis

  DOI：10.1021/ja01230a047

  日期：1944.2
• 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
  申请人：Bonfanti Jean-Francois

  公开号：US20070093502A1

  公开（公告）日：2007-04-26

  The present invention concerns 5- or 6-substituted-benzimidazole derivatives having inhibitory activity on the replication of the respiratory syncytial virus and having the formula a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein Q is Ar 2 , R 6 , pyrrolidinyl substituted with R 6 , piperidinyl substituted with R 6 or homopiperidinyl substituted with R 6 , G is a direct bond or optionally substituted C 1-10 -alkanediyl; R 1 is Ar 1 or a monocyclic or bicyclic heterocycle; one of R 2a and R 2b is cyanoC 1-6 alkyl, cyanoC 2-6 alkenyl, Ar 3 C 1-6 alkyl, Het-C 1-6 alkyl, N(R 8a R 8b )C 1-6 alkyl, Ar 3 C 2-6 alkenyl, Het-C 2-6 alkenyl, Ar 3 aminoC 1-6 alkyl, Het-aminoC 1-6 alkyl, Ar 3 thioC 1-6 alkyl, Het-thioC 1-6 alkyl, Ar 3 sulfonylC 1-6 alkyl, Het-sulfonylC 1-6 alkyl, Ar 3 aminocarbonyl, Het-aminocarbonyl, Ar 3 (CH 2 ) n aminocarbonyl, Het-(CH 2 ) n aminocarbonyl, Ar 3 carbonylamino, Het-carbonylamino, Ar 3 (CH 2 ) n carbonylamino, Het-(CH 2 ) n carbonylamino, and the other one of R 2a and R 2b is hydrogen; in case R 2a is hydrogen, then R 3 is hydrogen; in case R 2b is hydrogen, the R 3 is hydrogen or C 1-6 alkyl. It further concerns their preparation and compositions comprising them, as well as their use as a medicine.
• 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION
  申请人：Bonfanti Jean-Francois

  公开号：US20090062278A1

  公开（公告）日：2009-03-05

  The present invention concerns 5- or 6-substituted-benzimidazole derivatives having inhibitory activity on the replication of the respiratory syncytial virus and having the formula a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein Q is Ar 2 , R 6 , pyrrolidinyl substituted with R 6 , piperidinyl substituted with R 6 or homopiperidinyl substituted with R 6 , G is a direct bond or optionally substituted C 1-10 alkanediyl; R 1 is Ar 1 or a monocyclic or bicyclic heterocycle; one of R 2a and R 2b is cyanoC 1-6 alkyl, cyanoC 2-6 alkenyl, Ar 3 C 1-6 alkyl, Het 1 C 1-6 alkyl, N(R 8a R 8b )C 1-6 alkyl, Ar 3 C 2-6 alkenyl, Het 1 C 2-6 alkenyl, Ar 3 aminoC 1-6 alkyl, Het 1 aminoC 1-6 alkyl, Ar 3 thioC 1-6 alkyl, Het 1 thioC 1-6 alkyl, Ar 3 sulfonylC 1-6 alkyl, Het 1 sulfonylC 1-6 alkyl, Ar 3 aminocarbonyl, Het 1 aminocarbonyl, Ar 3 (CH 2 ) n aminocarbonyl, Het 1 (CH 2 ) n aminocarbonyl, Ar 3 carbonylamino, Het 1 carbonylamino, Ar 3 (CH 2 ) n carbonylamino, Het 1 (CH 2 ) n carbonylamino, and the other one of R 2a and R 2b is hydrogen; in case R 2a is hydrogen, then R 3 is hydrogen; in case R 2b is hydrogen, the R 3 is hydrogen or C 1-6 alkyl. It further concerns their preparation and compositions comprising them, as well as their use as a medicine.
• US4925984A
  申请人：——

  公开号：US4925984A

  公开（公告）日：1990-05-15